Health Canada has approved Cymbalta® (duloxetine HCl) for the symptomatic relief of anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD), Eli Lilly Canada Inc. and Boehringer Ingelheim (Canada) Ltd. announced today.
The details can be read here.
No comments:
Post a Comment